Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Neuren Pharmaceuticals (NEU AU)
Watchlist
74
Analysis
Health Care
•
Australia
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company. The Company researches neurological and metabolic disorders.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Data#3 Ltd
•
19 Jul 2023 05:09
S&P/ASX200 Ad Hoc Index Rebalance & Update to Potential Changes in September
Ventia replaces Blackmores in the ASX200 at the close on 21 July. That also leads to changes to potential adds/deletes in September. WBT and DTL...
Brian Freitas
Follow
807 Views
Share
bullish
•
Ventia
•
18 Jul 2023 23:04
Ventia Services (VNT) Selected to Join ASX 200 - Not A Surprise
Ventia (VNT AU) was chosen to join the S&P ASX 200 on Friday's close, replacing Blackmores. It was not that much of a surprise. There have been...
Travis Lundy
Follow
771 Views
Share
bullish
•
Neuren Pharmaceuticals
•
16 Jul 2023 11:56
Quiddity Leaderboard ASX Sep 23: Intra-Review Replacement for BKL and Many Other Expected Changes
Blackmores Ltd could be deleted from the ASX 200 index and Neuren Pharmaceuticals or Ventia could become the replacement. This could be announced...
Janaghan Jeyakumar, CFA
Follow
694 Views
Share
bullish
•
Neuren Pharmaceuticals
•
16 Jul 2023 05:30
Index Rebalance & ETF Flow Recap: ASX, Chinext, URA, Korea Stocks, NKY
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
861 Views
Share
bullish
•
Neuren Pharmaceuticals
•
14 Jul 2023 23:20
Neuren Pharmaceuticals (NEU AU): Shares Roar on Expanded Global Partnership for Newly Launched Drug
Neuren expanded Acadia’s trofinetide license to worldwide, for up to additional $527M to Neuren (including $100M up-front) plus mid-teens to low...
Tina Banerjee
Follow
684 Views
Share
First
Previous
8
9
10
11
12
13
14
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x